We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ESTRO-PESS (Aspen Pharmacare Australia Pty Ltd)
Product name
ESTRO-PESS
Date registered
Evaluation commenced
Decision date
Approval time
186 (255 working days)
Active ingredients
estradiol (as hemihydrate)
Registration type
New generic medicine
Indication
ESTRO-PESS (modified-release pessary) is indicated for the treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.
ESTRO-PESS is not intended for children or males.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine